The placenta is a highly vascular structure composed of both maternal and fetal elements. We have determined that damaging DOI of original article: https://doi
variants in genes responsible for the positive regulation of angiogenesis (PRA) (GO:0045766) that are inherited by the fetus impair fetal growth and placental function in pregnancies involving critical congenital cardiac defects (Russell et al., 2019) . In this dataset, we present the specific genetic variants identified, describe the parental origin of each variant where possible and present the analyses regarding the potential effects of parental origin of the variant on placental function and fetal growth. The data presented are related to the research article "Damaging variants in proangiogenic genes impair growth in fetuses with cardiac defects" (Russell et al., 2019) .
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Specifications Table   Subject area Biology More specific subject area Molecular Genetics Type of data Tables  How data was acquired Whole exome sequencing was performed as described in the related research article [1] . Exons were captured from fragmented and adaptor ligated genomic DNA samples using the SureSelect Human All Exon v.5 containing 51 Mb (Agilent Technologies, Santa Clara, CA). Paired-end 2x101-base massively parallel sequencing was carried out on the Illumina HiSeq2500 platform (Illumina, San Diego, CA), according to the manufacture's protocols. Base calling was performed by the Illumina CASAVA software (version 1.8.2) with default parameters.
Data format Analyzed Experimental factors
Sequencing reads were aligned to the human reference genome (GRCh37-derived alignment set used in 1000 Genomes Project) and the Genome Analysis Toolkit (GATK, v.2.6e5) was used to generate variant calls as previously described [1] .
Experimental features
Families delivering a baby with a congenital heart defect (CHD) requiring surgical repair in infancy were recruited for the study. Experimental methods were described in the related research article. 1 Briefly, (i) The placenta and neonate were weighed and measured.
(ii) Exome sequencing was performed on the subjects (N ¼ 133) and their parents (N ¼ 114 parent-child trios and 15 parent-child duos).
(iii) The GeneVetter analysis tool (default settings) was used to identify damaging coding sequence variants in genes identified as positive regulators of angiogenesis (PRA) (GO:0045766 
Data
We performed exome sequencing on infants with critical congenital heart disease (N ¼ 133) and their parents (N ¼ 114 parent-child trios and 15 parent-child duos). Using the GeneVetter program, we
Value of the data
The presented data will facilitate the evaluation of fetal and maternal genetic variation on placental function and fetal growth in pregnancies involving a fetus with a CHD. The data will directly benefit investigators examining the relationship between fetal growth and development and clinical outcomes in infants with critical CHD. In the accompanying tables, different ways of grouping the data are used to examine the effects of inherited and not inherited genetic variation on placental function and fetal growth. The value of the data will be in the stimulation of ideas and approaches to estimate these complex genetic relationships.
Of particular interest is the potential interaction effect of damaging PRA variants present in both the mother and fetus. The interaction effect will require a much larger cohort to adequately assess; the presentation of the aggregate data using several different approaches will allow merging of the data with that from ongoing and future efforts.
Table 1
Positive Regulation of Angiogenesis (PRA) gene set (GO:0045766).
Positive Regulation of Angiogenesis (PRA)   ABL1  CX3CR1  HSPB1  PTGS2  ACVRL1  CXCL8  HSPB6  PTK2B  ADAM12  CXCR2  HYAL1  RAMP2  ADM  CYBB  IL10  RAPGEF3  ADM2  CYP1B1  IL1A  RHOB  AGGF1  CYSLTR2  IL1B  RHOJ  AGO2  DDAH1  ISL1  RLN2  AGTR1  DLL1  ITGA5  RRAS  AKT3  ECM1  ITGB1  RUNX1  ANGPT2  Emilin2  ITGB2  S100A1  ANGPT4  ENG  ITGB8  SASH1  ANGPTL3  EPHA1  JAK1  SEMA5A  ANGPTL4  ERAP1  JCAD  SERPINE1  ANXA1  ETS1  JUP  SFRP2  ANXA3  F3  KDR  SIRT1  APELA  FGF1  KLF4  SIRT6  APLNR  FGF18  LRG1  SMAD1  AQP1  FGF2  MAP3K3  SMOC2  BMPER  FGFBP1  MTDH  SP1  BRCA1  FLT1  MYDGF  SPHK1  BTG1  FOXC2  NFE2L2  SRPX2  C3  GAB1  NODAL  STAT3  C3AR1  GATA2  NOS3  STIM1  C5  GATA4  NR2E1  TBXA2R  C5AR1  GATA6  NRP1  TEK  C6  GDF2  PAK4  TN-W  CCBE1  GHRL  PDCD6  TERT  CCL11  GHSR  PDCL3  TGFBR2  CCL24  GREM1  PDPK1  THBS1  CCR3  HDAC7  PGF  TLR3  CD34  HDAC9  PIK3C2A  TMIGD2  CD40  HGF  PIK3R6  TNFSF12  CDH5  HIF1A  PLCG1  TWIST1  CELA1  HIPK1  PLK2  UTS2R  CHI3L1  HIPK2  PPP1R16B  VASH2  CHRNA7  HK2  PRKCA  VEGFA  CIB1  HMGA2  PRKCB  VEGFB  CMA1  HMGB1  PRKD1  VEGFC  CTSH  HMOX1  PRKD2  VEGFD  CX3CL1  HPSE  PTGIS  WNT5A  XBP1 ZC3H12A ZNF304 identified 113 pathogenic variants in the 163 positive regulators of angiogenesis (PRA) genes (Table 1) in 73 subjects (see Table 2 for specific variants identified in the probands). To estimate the effects of the parental damaging PRA variants on placental function and fetal growth, we grouped the data to examine the effects from different perspectives. First, we examined the effects from the fetal perspective to assess whether a variant inherited or not inherited from either parent had an effect on placental function and fetal growth (Table 3) . To remove the effects of having variants in both parents, we next restricted analysis to those cases where only a single parent had identified pathogenic variants (Table 4) . Lastly, to specifically assess the effects of maternal variants on placental function and fetal growth, we grouped all cases based on the presence or absence of maternal variants that were inherited or not inherited (Table 5 ). The presented data will allow the examination of the effects of parental origin of inherited and not inherited variants on placental function and fetal growth in pregnancies involving CHD. In addition, it is anticipated that the different approaches to grouping the Table 3 Effect of parental damaging PRA variants on placental function and fetal growth. The data is evaluated from the fetal perspective. For example, for the question, "Was there a variant in the father that was inherited by the infant?", the "No" answer will include cases in which the father had no variants and cases in which the father did have a variant but it wasn't inherited by the proband. x P-value from two-sample t-test.
Table 4
Effect of parental origin of damaging PRA variants on placental function and fetal growth. The data only includes those cases in which inherited variants or not inherited variants originate from a single parent. For example, for the question, "Was there a variant in the father that was inherited by the infant?", the "Yes" answer includes only those cases in which one or more variants were inherited from the father and no variants were inherited from the mother. Similarly, for the question, "Was there a variant in the father that wasn't inherited by the infant?", only those cases in which no PRA variant was noted in the proband and there were 1 or more variants in the father were included. cases for analysis will help in the design and analysis of future work examining parental genetic factors impacting the maternal-fetal environment and fetal growth.
Experimental design, materials, and methods
For a complete description of the experimental design and methods, please see the related research article [1] . Briefly, whole exome sequencing was performed on 133 subjects and all consented parents (114 parent-child trios, 15 parent-child duos and 4 child only). Exons were captured from fragmented and adaptor ligated genomic DNA samples using the SureSelect Human All Exon v.5 containing 51 Mb (Agilent Technologies, Santa Clara, CA). Paired-end 2 Â 101-base massively parallel sequencing was carried out on the Illumina HiSeq2500 platform (Illumina, San Diego, CA), according to the manufacture's protocols. Base calling was performed by the Illumina CASAVA software (version 1.8.2) with default parameters. Sequencing reads passing the quality filter were aligned to the human reference genome (GRCh37-derived alignment set used in 1000 Genomes Project) with Burrows-Wheeler Aligner (BWA, v.0.7.12) and Dragen (Illumina, San Diego, CA) [2] . PCR duplicates were removed using Picard (v.1.97; Broad Institute, Boston, MA). The Genome Analysis Toolkit (GATK, v.2.6e5; Broad Institute, Boston, MA) was used to generate variant calls. The Gene Ontology (GO) database was used to identify the target gene set. The GO term "positive regulator of angiogenesis" (PRA) (GO:0045766) was selected to minimize potential opposing effects of damaging variants in positive and negative regulators. The PRA gene set contains 163 genes (Table 1) . Damaging variants in the PRA gene set were identified using the GeneVetter program, a web-based analysis tool designed to improve the accuracy of pathogenicity prediction for single nucleotide variants identified by exome sequencing [3] . To be adjudicated as damaging by using the program's default settings, a variant must meet all of the following criteria: (i) have a maximum allele frequency in the sample population of <0.05, (ii) be adjudicated as "Damaging" by at least 2 of 3 of the following algorithms: PolyPhen2, SIFT, and MutationTaster, and (iii) have a maximum allele frequency across European-Americans and AfricanAmericans of <0.005.
